Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia

NCT06743113 is registered in ClinicalTrials.gov with Hemanext as lead sponsor.

NCT NCT06743113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06743113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia
Lead sponsor
Hemanext
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
October 1, 2029
Enrollment
48 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anaemia, sickle cell anemia (hbss, or hbsβ-thalassemia0), sickle cell anemia crisis, sickle cell anemia in children